Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: trouble (31), riot (2), disorder (273)

DVd(Twice weekly)Daratumumab-Bortezomib-Dexamethasone Cycle 9 onwards

Description: Chemotherapy Protocol Myeloma Bortezomib (twice weekly) Daratumumab Dexamethasone Cycles 9 onwards Regimen • Myeloma – Bortezomib (twice weekly) with daratumumab and dexamethasone Note
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVdTwice-weeklyDaratumumab-Bortezomib-Dexamethasone-Cycle-9-onwards.pdf

VenetoclaxLow

Description: Chemotherapy Protocol Chronic Lymphocytic Leukaemia VENETOCLAX (low risk) Funding may be required for this regimen. Regimen • CLL – Venetoclax (low risk) Indication • Venetoclax is indicated for the trea
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/VenetoclaxLow.pdf

Carboplatin Paclitaxel EC Pembrolizumab Neoadjuvant Ver1.0

Description: Chemotherapy Protocol BREAST CANCER PEMBROLIZUMAB WITH CARBOPLATIN/PACLITAXEL AND EC NEOADJUVANT BREAST CANCER FOLLOWED BY ADJUVANT PEMBROLIZUMAB Regimen • Breast-Pembrolizumab with
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Carboplatin-Paclitaxel-EC-Pembrolizumab-Neoadjuvant.pdf

Azacitidine(SC)-Venetoclax

Description: Chemotherapy Protocol Acute Myeloid Leukaemia AZACITIDINE (SC) - VENETOCLAX Regimen  AML – Azacitidine (SC) - Venetoclax Indication  Newly diagnosed acute myeloid leukaemia (AML).
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/AML/AzacitidineSC-Venetoclax.pdf

VenetoclaxHigh

Description: Chemotherapy Protocol Chronic Lymphocytic Leukaemia VENETOCLAX (high risk) Regimen • CLL – Venetoclax (high risk) Indication • Venetoclax is indicated for the treatment of adult patients with chronic lymphocy
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/VenetoclaxHigh.pdf

ObinutuzumabVenetoclax LowRisk

Description: Chemotherapy Protocol Chronic Lymphocytic Leukaemia Obinutuzumab-Venetoclax (Low Risk) Regimen • CLL – Obinutuzumab-Venetoclax (Low Risk) Indication • Chronic lymphatic leukaemia (CLL) or small lymphocytic lymphoma (SLL)
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/ObinutuzumabVenetoclax-LowRisk.pdf

VR-RituximabVenetoclaxCycle_1_VenetoclaxDoseTitration

Description: Chemotherapy Protocol Chronic Lymphocytic Leukaemia VR-RITUXIMAB-VENETOCLAX (high risk) Cycle 1 – Venetoclax dose titration Regimen • CLL – VR Rituximab Venetoclax (high risk) Cycle 1 – Venetoclax dos
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/VR-RituximabVenetoclaxCycle-1-VenetoclaxDoseTitration.pdf

After a trigeminal injection - patient information

Description: This factsheet explains how to take care of your eyes, mouth and face after your trigeminal injection.
Url: /Media/UHS-website-2019/Patientinformation/Brain-and-spine/After-a-trigeminal-injection-1393-PIL.pdf

Unwise decisions

Description: Patients do not often disagree with the clinician who is treating them. When disagreement occurs, under some circumstances, this may lead
Url: /HealthProfessionals/Clinical-law-updates/Unwise-decisions.aspx

Incidental meningioma - patient information

Description: This factsheet explains what an incidental meningioma is, what this diagnosis means for you, and what follow-up care you will
Url: /Media/UHS-website-2019/Patientinformation/Brain-and-spine/Incidental-meningioma-3719-PIL.pdf

111 to 120 of 282

Previous … 10 11 12 13 14 … Next